Application of multiple b-value DWI in assessment of early treatment response in postoperative patients with glioma
2017-09-03,*,,,,
, *, , , ,
(1.Department of Medical Imaging, the Second Hospital of Hebei Medical University,Shijiazhuang 050000, China; 2.Department of Medical Imaging, HuanghuaMunicipal People's Hospital, Huanghua 061300, China)
Application of multiple b-value DWI in assessment of early treatment response in postoperative patients with glioma
SHUCaikun1,QUANGuanmin1*,YUANTao1,WEIJianhai2,ZHENGYongli1,LEIJianming1
(1.DepartmentofMedicalImaging,theSecondHospitalofHebeiMedicalUniversity,Shijiazhuang050000,China; 2.DepartmentofMedicalImaging,HuanghuaMunicipalPeople'sHospital,Huanghua061300,China)
Objective To evaluate the application value of ADC of different b-value ADC maps in multiple b-value DWI for assessment of early treatment response and detection of tumor progression. Methods Totally 47 postoperative patients with glioma were enrolled. All of them accepted chemoradiotherapy after operation. Conventional MRI and multiple b-value DWI (b=0, 1 000, 2 000, 3 000 s/mm2) scans were performed. The mean and minimal ADC values (ADCmeanand ADCmin) were measured in 5 differrent corresponding ADC maps, such as ADC(1 000/0), ADC(/2 000/0), ADC(3 000/0), ADC(3 000/1 000)and ADC(3 000/2 000). And the relative values (rADCmeanand rADCmin) were calculated. The differences of ADC values among different reaction types (complete response, partial response, stable disease and progressive disease)and between progressive and non-progressive groups were compared. ROC analysis was used to determine the best cutoff values and diagnostic efficiency of ADCvalue for diagnosis of tumor progression. Results The rADCmeanin ADC(3 000/0), ADC(3 000/1 000)and ADC(3 000/2 000)maps were significantly different among different response types and between progressive group and non-progressive group (allP<0.05). The ADCmeanin ADC(3 000/1 000)and ADC(3 000/2 000)maps were significantly different among different response types and between progressive group and non-progressive group (allP<0.05). The ADCmeanand rADCmeanin ADC(3 000/2 000)map had the maximum area under curve (0.86, 0.84). When ADCmeanand rADCmeanin ADC3 000/2 000map were 408.65×10-6mm2/s and 1.12, the sensitivities and specificities were 89.3%, 71.0% and 92.9%, 77.4%, respectively. Conclusion The ADCmeanand rADCmeanin high b-value ADC maps are helpful to discriminate the early treatment response from tumor progression, which can provide valuable information for identification of tumor progression of glioma after treatment.
Glioma; Therapy; Diffusion magnetic resonance imaging; Apparent diffusion coefficient; Tumor progression
胶质瘤是中枢神经系统最常见的原发肿瘤,手术切除联合术后放疗或放化疗是目前最有效的治疗方式[1],但多数胶质瘤生长具有侵袭性,术后复发率较高。对胶质瘤术后放化疗的患者定期复查评估治疗效果及早期发现肿瘤进展,对临床及时调整治疗方案和预测患者预后十分重要。常规MRI对胶质瘤治疗反应的监测主要通过FLAIR序列高信号和异常强化信号病灶的变化评估,但部分治疗反应的常规MRI表现与肿瘤进展存在较多重叠。功能MRI有助于鉴别肿瘤进展与治疗反应[2-3],DWI是其中最易获取且广泛应用的方法,通过探测组织内水分子的扩散受限程度间接反映组织结构和细胞特性,且高b值DWI对扩散受限更敏感,但目前关于b=1 000 s/mm2的DWI能否鉴别肿瘤进展与治疗反应仍存在争议[1]。有关高b值DWI鉴别胶质瘤进展的研究报道少见[4-5]。本研究比较不同b值ADC图的ADC值评估肿瘤治疗效果和鉴别肿瘤进展的价值,探讨评估胶质瘤治疗反应DWI的最适b值和最适ADC图。
1 资料与方法
1.1 一般资料 收集2014年9月—2015年10月间具有完整资料的脑胶质瘤术后放化疗患者47例,男29例,女18例,年龄7~84岁,平均(44.0±16.6)岁。纳入标准:①经手术病理确诊为胶质瘤;②术后接受联合放化疗,放疗剂量总剂量60 Gy;③在放化疗前1天及结束后2天接受MR扫描,之后每间隔3个月随访复查MRI;④随访时间>6个月。排除标准:①MR检查禁忌证;②治疗结束后2天MRI无明显异常强化病灶;③治疗后随访未行MR扫描;④DWI图像伪影(运动伪影和异物伪影)明显,影响诊断。47例患者中,WHO Ⅱ级6例,包括5例弥漫性星形细胞瘤、1例少突-星形细胞瘤;Ⅲ……
猜你喜欢
杂志排行
中国医学影像技术的其它文章
- Progresses of CAIPIRINHA-Dixon-TWIST-VIBE in diagnosis of small hepatocellular carcinoma
- Progresses of hybrid PET/MR in quantificative evaluation of cerebral blood flow
- Stability tests and action limits setting for central frequency and transmitter gain of MRI scanners
- MRI features and differential diagnosis of spinal epidural angiolipomas
- Application of estimation equations for glomerular filtration rate intype 2 diabetes mellitus
- Hematolymphangioma of left adrenal gland: Case report
